JP2016519124A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016519124A5 JP2016519124A5 JP2016511042A JP2016511042A JP2016519124A5 JP 2016519124 A5 JP2016519124 A5 JP 2016519124A5 JP 2016511042 A JP2016511042 A JP 2016511042A JP 2016511042 A JP2016511042 A JP 2016511042A JP 2016519124 A5 JP2016519124 A5 JP 2016519124A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- concentration
- seq
- antibody
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000009472 formulation Methods 0.000 claims 32
- 239000000203 mixture Substances 0.000 claims 32
- 239000000427 antigen Substances 0.000 claims 8
- 102000036639 antigens Human genes 0.000 claims 8
- 108091007433 antigens Proteins 0.000 claims 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims 7
- 239000012634 fragment Substances 0.000 claims 6
- 239000007853 buffer solution Substances 0.000 claims 5
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 4
- 229930195725 Mannitol Natural products 0.000 claims 4
- 239000007983 Tris buffer Substances 0.000 claims 4
- 239000000594 mannitol Substances 0.000 claims 4
- 235000010355 mannitol Nutrition 0.000 claims 4
- 239000008363 phosphate buffer Substances 0.000 claims 4
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 4
- 229920000053 polysorbate 80 Polymers 0.000 claims 4
- 229940068968 polysorbate 80 Drugs 0.000 claims 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims 4
- 229930006000 Sucrose Natural products 0.000 claims 3
- 239000002736 nonionic surfactant Substances 0.000 claims 3
- 239000005720 sucrose Substances 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 102000004388 Interleukin-4 Human genes 0.000 claims 2
- 108090000978 Interleukin-4 Proteins 0.000 claims 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 229920000136 polysorbate Polymers 0.000 claims 2
- 229950008882 polysorbate Drugs 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 101100152731 Arabidopsis thaliana TH2 gene Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 239000000872 buffer Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000000600 disaccharide group Chemical group 0.000 claims 1
- 150000002016 disaccharides Chemical class 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 125000000185 sucrose group Chemical group 0.000 claims 1
- 239000012905 visible particle Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361816899P | 2013-04-29 | 2013-04-29 | |
| US61/816,899 | 2013-04-29 | ||
| EP14305160.5 | 2014-02-05 | ||
| EP14305160 | 2014-02-05 | ||
| PCT/EP2014/058733 WO2014177568A1 (en) | 2013-04-29 | 2014-04-29 | Anti-il-4/anti-il-13 bispecific antibody formulations |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019004836A Division JP2019070025A (ja) | 2013-04-29 | 2019-01-16 | 抗ｉｌ−４／抗ｉｌ−１３二特異的抗体製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016519124A JP2016519124A (ja) | 2016-06-30 |
| JP2016519124A5 true JP2016519124A5 (cg-RX-API-DMAC7.html) | 2017-06-22 |
| JP6470261B2 JP6470261B2 (ja) | 2019-02-13 |
Family
ID=50159179
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016511042A Active JP6470261B2 (ja) | 2013-04-29 | 2014-04-29 | 抗ｉｌ−４／抗ｉｌ−１３二特異的抗体製剤 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US10005835B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2991678B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6470261B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102307257B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN105339004B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2014261497B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2910693C (cg-RX-API-DMAC7.html) |
| CL (1) | CL2015003193A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL242372B2 (cg-RX-API-DMAC7.html) |
| MX (1) | MX378502B (cg-RX-API-DMAC7.html) |
| MY (1) | MY178837A (cg-RX-API-DMAC7.html) |
| PH (1) | PH12015502441B1 (cg-RX-API-DMAC7.html) |
| RU (1) | RU2690850C2 (cg-RX-API-DMAC7.html) |
| SG (2) | SG10201708746RA (cg-RX-API-DMAC7.html) |
| TW (1) | TWI679019B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014177568A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| AR085911A1 (es) | 2011-03-16 | 2013-11-06 | Sanofi Sa | Dosis terapeutica segura de una proteina similar a un anticuerpo con region v dual |
| US10434088B2 (en) | 2013-05-03 | 2019-10-08 | Selecta Biosciences, Inc. | Methods related to administering immunosuppressants and therapeutic macromolecules at a reduced pharmacodynamically effective dose |
| TW201628647A (zh) | 2014-06-27 | 2016-08-16 | 賽諾菲公司 | 抗－ｉｌ４－ｉｌ１３雙特異性抗體 |
| KR101776879B1 (ko) * | 2015-01-19 | 2017-09-08 | 주식회사 녹십자 | 항-egfr 항체를 포함하는 약학 제제 |
| BR112018014123A2 (pt) * | 2016-01-12 | 2018-12-11 | Dr. Reddy's Laboratories Limited | formulação farmacêutica aquosa estável. |
| EA037960B1 (ru) | 2016-04-27 | 2021-06-15 | Эббви Инк. | Способ лечения эозинофильного эзофагита с применением антитела против il-13 |
| US20180193003A1 (en) | 2016-12-07 | 2018-07-12 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
| CA3048381A1 (en) | 2016-12-28 | 2018-07-05 | Jcr Pharmaceuticals Co., Ltd. | Lyophilized preparation |
| WO2018183932A1 (en) | 2017-03-30 | 2018-10-04 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with a il-13 inhibitor |
| US11603407B2 (en) * | 2017-04-06 | 2023-03-14 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
| JOP20190255A1 (ar) | 2017-04-28 | 2019-10-27 | Amgen Inc | صيغ أجسام مضادة لـ rankl بشري، وطرق لاستخدامها |
| CA3063324A1 (en) | 2017-05-16 | 2018-11-22 | Bhami's Research Laboratory, Pvt. Ltd. | High concentration protein formulations with reduced viscosity |
| TWI795415B (zh) | 2017-07-07 | 2023-03-11 | 日商安斯泰來製藥股份有限公司 | 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段 |
| EP3795590A4 (en) | 2018-05-17 | 2022-05-04 | Astellas Pharma Inc. | COMPLEX WITH ANTI-HUMAN MUC1 ANTIBODY FAB FRAGMENT, PEPTIDE LINKER AND/OR LIGAND |
| EP3849513A1 (en) * | 2018-09-11 | 2021-07-21 | Ichnos Sciences SA | Compositions comprising a bispecific antibody, bufffer and one or more stabilizing agents |
| CN112789028A (zh) * | 2018-10-01 | 2021-05-11 | 美国安进公司 | 用于减少双特异性抗体的聚集的方法 |
| US12065503B2 (en) | 2018-10-10 | 2024-08-20 | Astellas Pharma Inc. | Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex |
| KR102131519B1 (ko) * | 2018-10-30 | 2020-07-07 | 가톨릭대학교 산학협력단 | 간암 전이 진단 또는 예후 예측용 바이오마커 및 이의 용도 |
| JP7482866B2 (ja) | 2018-11-19 | 2024-05-14 | ビオラ・セラピューティクス・インコーポレイテッド | 生物学的治療薬による疾患処置方法およびデバイス |
| JOP20210229A1 (ar) | 2019-02-18 | 2023-01-30 | Lilly Co Eli | صيغة جسم مضاد علاجي |
| KR20220012894A (ko) | 2019-05-24 | 2022-02-04 | 사노피 | 전신 경화증의 치료 방법 |
| GB201911461D0 (en) * | 2019-08-09 | 2019-09-25 | Arecor Ltd | Novel composition |
| CN121197633A (zh) | 2019-12-13 | 2025-12-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
| US20210308058A1 (en) * | 2020-03-11 | 2021-10-07 | Selecta Biosciences, Inc. | Methods and compositions related to synthetic nanocarriers |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| ATE139258T1 (de) | 1990-01-12 | 1996-06-15 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5869619A (en) | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| AU5632296A (en) | 1995-04-27 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| EP2305027B1 (en) | 1996-12-03 | 2014-07-02 | Amgen Fremont Inc. | Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom |
| ATE200679T1 (de) | 1997-04-14 | 2001-05-15 | Micromet Ag | Neues verfahren zur herstellung von anti-humanen antigenrezeptoren und deren verwendungen |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| US20040023338A1 (en) | 2001-10-26 | 2004-02-05 | Heavner George A. | IL-4 mutein proteins, antibodies, compositions, methods and uses |
| EP1578912A4 (en) | 2001-10-26 | 2007-12-26 | Centocor Inc | IL-13 MUTEIN PROTEINS, ANTIBODIES, COMPOSITIONS, METHODS AND USES |
| US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
| TWI307630B (en) * | 2004-07-01 | 2009-03-21 | Glaxo Group Ltd | Immunoglobulins |
| US20060148009A1 (en) | 2004-10-12 | 2006-07-06 | Xencor, Inc. | Prediction and assessment of immunogenicity |
| AR064826A1 (es) * | 2007-01-09 | 2009-04-29 | Wyeth Corp | Formulaciones de anticuerpos anti-il-13 y usos de los mismos. dispositivos, parche y jeringa |
| EP2050764A1 (en) * | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| WO2009070642A1 (en) | 2007-11-28 | 2009-06-04 | Medimmune, Llc | Protein formulation |
| EP2196476A1 (en) | 2008-12-10 | 2010-06-16 | Novartis Ag | Antibody formulation |
| US20120121580A1 (en) * | 2009-07-28 | 2012-05-17 | Merck Sharp & Dohme Corp. | Methods for producing high concentration lyophilized pharmaceutical formulations |
| SG183983A1 (en) * | 2010-03-17 | 2012-10-30 | Abbott Res Bv | Anti-nerve growth factor (ngf) antibody compositions |
| AR085911A1 (es) * | 2011-03-16 | 2013-11-06 | Sanofi Sa | Dosis terapeutica segura de una proteina similar a un anticuerpo con region v dual |
| TWI743461B (zh) | 2011-03-28 | 2021-10-21 | 法商賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
| JOP20200043A1 (ar) * | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
| JO3625B1 (ar) * | 2011-09-22 | 2020-08-27 | Amgen Inc | بروتينات رابطة للأنتيجين cd27l |
| CN102961745B (zh) * | 2012-09-27 | 2015-02-18 | 苏州康聚生物科技有限公司 | 抗体组合物制剂及其应用 |
-
2014
- 2014-04-25 TW TW103114922A patent/TWI679019B/zh active
- 2014-04-29 US US14/787,507 patent/US10005835B2/en active Active
- 2014-04-29 CA CA2910693A patent/CA2910693C/en active Active
- 2014-04-29 MX MX2015015152A patent/MX378502B/es unknown
- 2014-04-29 MY MYPI2015703782A patent/MY178837A/en unknown
- 2014-04-29 CN CN201480037173.9A patent/CN105339004B/zh active Active
- 2014-04-29 IL IL242372A patent/IL242372B2/en unknown
- 2014-04-29 WO PCT/EP2014/058733 patent/WO2014177568A1/en not_active Ceased
- 2014-04-29 AU AU2014261497A patent/AU2014261497B2/en active Active
- 2014-04-29 RU RU2015150149A patent/RU2690850C2/ru active
- 2014-04-29 JP JP2016511042A patent/JP6470261B2/ja active Active
- 2014-04-29 EP EP14724659.9A patent/EP2991678B1/en active Active
- 2014-04-29 SG SG10201708746RA patent/SG10201708746RA/en unknown
- 2014-04-29 SG SG11201508682RA patent/SG11201508682RA/en unknown
- 2014-04-29 KR KR1020157032914A patent/KR102307257B1/ko active Active
-
2015
- 2015-10-22 PH PH12015502441A patent/PH12015502441B1/en unknown
- 2015-10-29 CL CL2015003193A patent/CL2015003193A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016519124A5 (cg-RX-API-DMAC7.html) | ||
| RU2015150149A (ru) | Составы на основе биспецифических антител к il-4/il-13 | |
| WO2021244089A1 (zh) | 新型冠状病毒（sars-cov-2）刺突蛋白结合分子及其应用 | |
| AU2016363455B2 (en) | Full human antibody against respiratory syncytial virus | |
| PE20181952A1 (es) | Anticuerpos anti-ll-33, composiciones, metodos y usos de los mismos | |
| HRP20191219T1 (hr) | Molekule protutijela koje imaju specifičnost za ljudski ox40 | |
| RU2014101707A (ru) | АНТИ-Axl АНТИТЕЛА И ИХ ПРИМЕНЕНИЕ | |
| JP2012254092A5 (cg-RX-API-DMAC7.html) | ||
| JP2011527899A5 (cg-RX-API-DMAC7.html) | ||
| JP2018521638A5 (cg-RX-API-DMAC7.html) | ||
| JP2019536806A5 (cg-RX-API-DMAC7.html) | ||
| JP2012525829A5 (cg-RX-API-DMAC7.html) | ||
| IL299072A (en) | Antibodies and methods of use thereof | |
| PE20121646A1 (es) | Anticuerpo anti-tslp modificado por tecnicas de ingeneria genetica | |
| RU2019132843A (ru) | Антитело против в7-н3, его антигенсвязывающий фрагмент и их медицинское применение | |
| RU2018102606A (ru) | Молекулы, связывающиеся с psl pseudomonas, и пути их применения | |
| CN103396481B (zh) | 一种二型登革热病毒ns1蛋白的重链单域抗体及其制备方法和应用 | |
| JP2012518425A5 (cg-RX-API-DMAC7.html) | ||
| JP2016509009A5 (cg-RX-API-DMAC7.html) | ||
| HRP20170568T1 (hr) | Protutijela anti-ox40 i postupci za njihovu uporabu | |
| JP2011527902A5 (cg-RX-API-DMAC7.html) | ||
| JP2014519334A5 (cg-RX-API-DMAC7.html) | ||
| EA201190275A1 (ru) | Белок, связывающий интерлейкин-13 (il-13) | |
| AR075849A1 (es) | Moleculas de anticuerpos que tienen especificidad de union por il-13 humana | |
| JP2018520334A5 (cg-RX-API-DMAC7.html) |